List of Excipients in Branded Drug BYOOVIZ

« Back to Dashboard

BYOOVIZ Excipient Strategy and Commercial Opportunities in Ranibizumab Biosimilars

Last updated: October 18, 2026

BYOOVIZ (ranibizumab-nuna) uses a conventional, reference-aligned excipient system: histidine buffer, polysorbate 20, trehalose dihydrate, and water for injection. The formulation supports a preservative-free, single-dose ophthalmic injection that closely matches Lucentis (ranibizumab) while minimizing formulation-related biosimilarity risk. Commercial opportunity is concentrated in manufacturing cost, supply reliability, ophthalmology channel access, and bundled delivery services rather than in creating a differentiated excipient profile.

BYOOVIZ is a biosimilar to Lucentis, developed by Samsung Bioepis and commercialized in the United States by Biogen. The FDA approved it in September 2021 for the same principal ophthalmic indications as Lucentis, including neovascular age-related macular degeneration, macular edema following retinal vein occlusion, and diabetic macular edema or diabetic retinopathy in specified patients.[1]

What excipients are used in BYOOVIZ?

BYOOVIZ contains ranibizumab-nuna at 10 mg/mL in a buffered, isotonic formulation intended for intravitreal injection.

Formulation component	Function	Commercial relevance
Histidine and histidine hydrochloride	pH control and buffering	Supports protein stability in the mildly acidic formulation range
Polysorbate 20	Surfactant	Limits adsorption and agitation-induced aggregation
Trehalose dihydrate	Stabilizer and tonicity contributor	Helps protect the antibody fragment during storage and handling
Water for injection	Vehicle	Supports a sterile, injectable presentation
No antimicrobial preservative	Preservative-free design	Appropriate for single-dose intravitreal administration

The FDA prescribing information identifies a formulation containing 10 mg/mL ranibizumab-nuna, 10 mM histidine hydrochloride, 0.01% polysorbate 20, and 5% trehalose dihydrate at approximately pH 5.5.[1] The commercial presentation is a single-dose vial containing 0.05 mL, equivalent to a 0.5 mg dose.

Why does BYOOVIZ use trehalose?

Trehalose is a nonreducing disaccharide used in biologic formulations to stabilize proteins during storage. It can reduce conformational stress and help maintain product quality during temperature excursions and freezing or drying processes.

In BYOOVIZ, trehalose also contributes to formulation tonicity. Its use is consistent with the formulation architecture of ranibizumab products and reduces the need for a novel excipient strategy that could introduce additional analytical or clinical comparability questions.

Trehalose is widely used in injectable biologics, which generally reduces regulatory novelty. Its main commercial risks are raw-material quality, lot consistency, microbial control, and supply continuity rather than regulatory acceptance.

Why is polysorbate 20 important?

Polysorbate 20 reduces protein adsorption to vial surfaces and limits aggregation caused by agitation, air-liquid interfaces, and handling. These risks are relevant for ranibizumab because intravitreal products require low particulate levels and tight control of visible and subvisible particles.

Polysorbate degradation can generate peroxides and free fatty acids. Those degradation products may increase protein oxidation, aggregation, or particle formation. A commercial excipient strategy therefore must control:

• Peroxide and aldehyde content
• Hydrolysis and oxidation during storage
• Supplier-to-supplier variability
• Interaction with elastomer closures and container surfaces
• Particulate generation during filling and transport

Polysorbate 20 is commercially available from multiple qualified suppliers, but substitution requires comparability work. A lower-cost or alternative-grade material may create more risk than value if it changes degradation behavior or impurity profiles.

How does the BYOOVIZ formulation compare with Lucentis?

BYOOVIZ was designed to be highly similar to Lucentis, including its core excipient framework. This approach is commercially rational because excipient differentiation has limited value in a product administered by ophthalmologists through a single-use intravitreal injection.

Attribute	BYOOVIZ	Lucentis
Active ingredient	Ranibizumab-nuna	Ranibizumab
Product class	Biosimilar	Reference biologic
Strength	10 mg/mL	10 mg/mL
Typical 0.5 mg presentation	0.05 mL	0.05 mL
Buffer system	Histidine-based	Histidine-based
Surfactant	Polysorbate 20	Polysorbate 20
Sugar/stabilizer	Trehalose dihydrate	Trehalose-based formulation
Preservative	None	None
Administration	Intravitreal injection	Intravitreal injection
U.S. regulatory listing	Purple Book biologic	Reference biologic, not Orange Book-listed

The formulation similarity does not mean the products are identical. Biosimilarity is established through a totality-of-the-evidence assessment covering structural, functional, pharmacokinetic, immunogenicity, and clinical data.[2] Excipient similarity helps narrow the analytical gap but does not independently establish biosimilarity.

What commercial opportunities exist for BYOOVIZ excipients?

The strongest opportunity is cost and supply optimization, not a new excipient platform.

1. Qualified excipient supply

Suppliers can compete for pharmaceutical-grade trehalose, histidine, and polysorbate 20 used in sterile biologic manufacturing. The value proposition depends on:

• Reliable global supply
• Low bioburden and endotoxin levels
• Consistent peroxide profiles for polysorbate 20
• Documentation under pharmaceutical quality systems
• Change-control support
• Regional manufacturing redundancy

Excipient suppliers with strong biologics experience can gain share even when the formulation itself is not proprietary.

2. Polysorbate stabilization and impurity control

Analytical services and excipient manufacturers can offer differentiated control strategies for polysorbate 20, including peroxide testing, fatty-acid profiling, degradation monitoring, and compatibility studies.

This is a higher-value opportunity than simple commodity supply because formulation performance can be affected by small changes in surfactant quality. Suppliers that provide validated analytical methods, stability data, and change-management packages may reduce customer qualification costs.

3. Low-particle ophthalmic manufacturing

The intravitreal route places a premium on particle control. Contract manufacturers can differentiate through:

• Low-shear formulation and filling
• Closed-system sterile processing
• Low-particle vial and stopper systems
• Container-closure integrity testing
• Automated visual inspection
• Subvisible particle characterization
• Reduced hold times before filling

These services can support BYOOVIZ production without changing the approved excipient composition.

4. Single-dose presentation and administration efficiency

BYOOVIZ is supplied as a preservative-free, single-dose vial. Commercial value may come from improving the administration workflow rather than changing the formulation. Potential offerings include:

• Ready-to-use transfer devices
• Compatible sterile syringes
• Low-dead-volume components
• Standardized ophthalmic injection kits
• Pharmacy or ambulatory-surgery center preparation services
• Training systems for retinal specialists

Any combination product or delivery accessory must preserve sterility, dose accuracy, container-closure integrity, and product compatibility.

What formulation patents protect BYOOVIZ?

The key legal distinction is between patents covering the ranibizumab reference product and patents owned by the biosimilar sponsor.

BYOOVIZ entered under the FDA biosimilar pathway. Its approval did not require the sponsor to obtain a new patent estate covering the existing ranibizumab formulation. The relevant intellectual-property risks historically centered on Lucentis formulation, dosing, use, manufacturing, and related biologic patents held by Genentech, Roche, or affiliated entities.

IP category	Relevance to BYOOVIZ
Ranibizumab composition patents	Generally directed to the active biologic or molecular construct
Formulation patents	May cover concentrations, buffers, stabilizers, surfactants, or storage conditions
Method-of-use patents	May cover retinal indications, dosing intervals, or patient subgroups
Manufacturing patents	May cover cell culture, purification, or formulation processes
Device or packaging patents	May affect injection components and presentation
Biosimilar applicant patents	May protect process improvements but do not automatically create market exclusivity

A formulation that uses histidine, polysorbate 20, and trehalose is unlikely to provide meaningful standalone exclusivity unless a patent claims a specific concentration range, stability profile, manufacturing process, container system, or combination of features. Broad excipient claims are difficult to enforce when the reference product already uses similar components.

When does BYOOVIZ lose exclusivity?

BYOOVIZ does not have a conventional small-molecule exclusivity timeline. It is a biologic approved under the Public Health Service Act and is listed in the FDA Purple Book rather than the Orange Book.[3]

The relevant barriers are:

• The reference product’s biologic exclusivity
• Patent litigation and settlement terms
• FDA biosimilar approval requirements
• Interchangeability status, if applicable
• Manufacturing capacity and commercial contracting

FDA approved BYOOVIZ in 2021, and the product entered the U.S. market in 2022 following resolution of commercial and patent-related barriers involving Lucentis. The main competitive issue is therefore not the expiration of BYOOVIZ exclusivity. It is the arrival of additional ranibizumab biosimilars and competing anti-VEGF products.

FDA has not assigned BYOOVIZ the same type of five-year new chemical entity exclusivity used for small molecules. The product’s market position depends on biosimilar competition, physician adoption, payer policy, and the relative economics of ranibizumab versus aflibercept and other retinal therapies.

What is the Orange Book status of BYOOVIZ?

BYOOVIZ is not an Orange Book drug because it is a biologic. The Orange Book primarily identifies approved drug products, therapeutic equivalence evaluations, and patent or exclusivity information for products regulated through the drug application framework.

BYOOVIZ is evaluated through the biologics framework and appears in the FDA Purple Book. The Purple Book identifies licensed biological products, reference products, biosimilars, and interchangeable biosimilars where applicable.[3]

This distinction affects litigation and generic-entry analysis. A conventional ANDA Paragraph IV challenge is not the primary pathway for BYOOVIZ competition.

Do Paragraph IV challenges apply to BYOOVIZ?

No. Paragraph IV certifications apply to patents listed in the Orange Book for products approved under the Federal Food, Drug, and Cosmetic Act. Biosimilar sponsors generally use the patent-dispute procedures established under the Biologics Price Competition and Innovation Act, often called the patent dance.

A biosimilar applicant may provide a confidential disclosure package, exchange patent information, negotiate a list of patents for potential litigation, and face an infringement action before or around commercial launch. The process differs from a generic ANDA Paragraph IV case.

For BYOOVIZ, the relevant commercial precedent is the resolution of patent and launch disputes associated with the Lucentis reference product. The launch timing reflected negotiated commercial and legal conditions rather than a simple Orange Book patent expiration.

What patent litigation affects BYOOVIZ?

The main litigation risk comes from patents covering Lucentis or ranibizumab-related uses, formulations, dosing regimens, and manufacturing methods. A biosimilar can be analytically similar yet still face a commercial launch delay if a patent owner asserts a valid and enforceable claim.

The risk profile is typically highest for:

• Broad formulation claims that cover the biosimilar’s excipient system
• Dosing claims covering treat-and-extend or maintenance regimens
• Indication claims covering retinal disease populations
• Manufacturing claims that read on upstream or downstream processes
• Device claims covering prefilled syringes or injection systems

The practical strength of a patent depends on claim scope, validity, enforceability, prosecution history, prior art, and the product’s actual manufacturing and clinical use. An excipient claim that requires a narrow concentration range may be avoided through formulation adjustment, but changes to an approved biosimilar formulation can trigger comparability and regulatory work.

How strong is the BYOOVIZ patent estate?

BYOOVIZ’s commercial strength is better understood as an execution and access position than as a broad proprietary excipient estate.

Strength factor	Assessment
Core formulation differentiation	Limited
Regulatory barrier to direct biosimilar competition	Moderate
Manufacturing complexity	Moderate to high
Excipient switching flexibility after approval	Limited
Supplier qualification burden	High
Physician switching barrier	Moderate
Payer-driven price pressure	High
Long-term protection from follow-on biosimilars	Limited

A biosimilar sponsor can obtain process, analytical, device, or formulation patents. Those patents may protect specific improvements, but they do not necessarily prevent other sponsors from developing a comparable ranibizumab product using a different process or presentation.

What generic and biosimilar launch risks exist?

BYOOVIZ faces several forms of competitive pressure.

Additional ranibizumab biosimilars

Additional sponsors can seek approval through the biosimilar pathway. Competition may reduce net price and make excipient cost control more important. Since the formulation is relatively standardized, suppliers with lower manufacturing costs may have an advantage.

Aflibercept biosimilars

Aflibercept products compete for many of the same retinal indications. Aflibercept biosimilars may shift ophthalmologist and payer preferences even when ranibizumab remains clinically appropriate.

Bevacizumab compounding

Off-label compounded bevacizumab can remain a low-cost alternative in retinal care. Its use depends on physician preference, payer policy, compounding quality, and patient-specific considerations.

Delivery innovations

Prefilled syringes and other administration formats can improve workflow and reduce preparation steps. A vial-based product may face commercial pressure if a competing product offers lower waste or easier administration.

What licensing deals support BYOOVIZ commercialization?

Samsung Bioepis developed BYOOVIZ, while Biogen obtained commercial rights in major markets, including the United States. The arrangement separates biosimilar development and manufacturing expertise from commercial infrastructure, market access, and ophthalmology sales capabilities.

For excipient and manufacturing partners, the relevant opportunity is typically through:

• Samsung Bioepis or its manufacturing network
• Biogen’s commercial and supply-chain organization
• Sterile injectable contract manufacturers
• Pharmaceutical-grade excipient suppliers
• Device and packaging vendors

Potential partnership value lies in supply assurance, regional fill-finish capacity, analytical testing, packaging, and ophthalmology distribution. A partner seeking a role in BYOOVIZ should expect rigorous qualification because small changes in excipient grade or container components can affect product quality.

What is the FDA regulatory status of BYOOVIZ?

FDA approved BYOOVIZ on September 17, 2021, as a biosimilar to Lucentis.[1] The approval covers the principal Lucentis indications identified in the prescribing information. BYOOVIZ is not designated interchangeable with Lucentis in the FDA labeling cited here.

The product is a sterile ophthalmic injection administered by intravitreal injection. The label contains warnings concerning endophthalmitis, retinal detachments, increases in intraocular pressure, thromboembolic events, and other risks associated with intravitreal anti-VEGF therapy.[1]

Regulatory opportunities are strongest in lifecycle management. A sponsor could seek a new presentation or delivery system, but any change must preserve product quality and demonstrate appropriate comparability.

What commercial strategy is most attractive for BYOOVIZ?

The most defensible strategy has five priorities:

1. Maintain the reference-aligned excipient system unless a clear cost or stability benefit justifies change.
2. Build dual-source capability for trehalose, histidine, polysorbate 20, vials, and elastomer closures.
3. Use polysorbate impurity and degradation control as a quality differentiator.
4. Improve fill-finish yield and reduce vial, syringe, and administration waste.
5. Compete through payer contracts, retinal-specialist access, and reliable supply rather than excipient novelty.

A new excipient would create regulatory and clinical risk without necessarily improving physician adoption. For an intravitreal biosimilar, the commercial return from a novel excipient is likely lower than the return from lower cost of goods, fewer supply interruptions, and a more efficient administration format.

Key Takeaways

• BYOOVIZ uses histidine buffer, polysorbate 20, trehalose dihydrate, and water for injection.
• The formulation is preservative-free and supplied as a single-dose intravitreal injection.
• Trehalose supports protein stability and tonicity; polysorbate 20 controls adsorption and aggregation.
• Excipient differentiation is less attractive than supply-chain and fill-finish optimization.
• Polysorbate 20 quality, peroxide control, and supplier redundancy are important commercial issues.
• BYOOVIZ is regulated as a biologic and is listed in the Purple Book, not the Orange Book.
• Paragraph IV litigation is not the primary legal pathway; BPCIA biosimilar patent procedures apply.
• The main competitive risks are additional ranibizumab biosimilars, aflibercept biosimilars, compounded bevacizumab, and improved delivery systems.
• The strongest commercial opportunities are low-particle sterile manufacturing, qualified excipient supply, administration efficiency, and payer-driven contracting.

FAQs

Can BYOOVIZ change from polysorbate 20 to polysorbate 80?

A change could be technically possible, but it would require substantial analytical comparability and regulatory assessment. Polysorbate type affects protein stability, degradation, particle formation, and container compatibility.

Is trehalose in BYOOVIZ protected by a separate patent?

Trehalose itself is a well-established excipient and is not a meaningful standalone exclusivity barrier for BYOOVIZ. Protection would more likely depend on a specific formulation, concentration, stability result, manufacturing process, or combination claim.

Does BYOOVIZ have a preservative advantage over multidose eye products?

Yes. Its single-dose, preservative-free presentation avoids the need for antimicrobial preservatives and is aligned with intravitreal administration requirements.

Could a prefilled BYOOVIZ syringe create a new commercial opportunity?

Yes. A prefilled presentation could reduce preparation steps and dose-transfer waste. It would require container-closure, stability, device compatibility, sterility, particulate, and human-factors work.

Which excipient creates the greatest manufacturing risk in BYOOVIZ?

Polysorbate 20 generally creates the most significant control challenge because oxidation, hydrolysis, and impurity variation can affect protein aggregation and particulate formation.

References

1. U.S. Food and Drug Administration. (2021). BYOOVIZ (ranibizumab-nuna) injection: Prescribing information. Biogen Inc.

2. U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2023). Questions and answers on biosimilar development and the BPCI Act: Guidance for industry. U.S. Department of Health and Human Services.

5. Biogen Inc. (2022). Biogen announces U.S. launch of BYOOVIZ, the first biosimilar to Lucentis. Company announcement.